Hugh Salter

Company: Anocca AB

Job title: Chief Scientific Officer & Vice President - Strategy & Translation

Seminars:

Introducing TCR-T Therapies Targeted at G12D & G12V KRAS-Mutated Solid Tumors to Utilize the Immune Response to Combat Cancer 5:45 pm

Presenting the characterization of TCR properties to improve T-cell therapies and enable more precise and effective targeting of cancer Showcasing the development of a comprehensive high-precision platform for TCRs as clinical assets, to accelerate the development of new therapies Understanding how the identification of candidates for KRAS G12 variants like G12D and G12V can expand…Read more

day: Conference Day One